Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharm) has signed a strategic collaboration agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. The partnership combines Sihuan Pharm’s end-to-end capabilities in drug development, large-scale manufacturing and global commercialisation with Biocytogen’s artificial-intelligence-enabled fully human antibody discovery platform.

The inaugural joint project targets obesity treatment. The investigational compound aims to raise energy expenditure while preserving or increasing muscle mass through an innovative mechanism of action, addressing a key unmet clinical need in global weight-management therapy.

Industry momentum toward “AI + high-throughput” research underpins the alliance. Biocytogen will supply its proprietary RenMice® target-humanised mouse models, in vivo efficacy platforms and AI-driven antibody discovery technologies to shorten development timelines, lower costs and enhance candidate screening efficiency.

Biocytogen, listed in Shanghai and Hong Kong, operates a gene-editing-based dual-engine platform encompassing a fully human antibody library and an extensive portfolio of target-humanised mouse models. As of 31 December 2025, the company had secured over 350 agreements covering more than 1,000 potential drug targets worldwide and maintains subsidiaries in China, the United States and Germany.

Sihuan Pharm, founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is an innovation-led medical-aesthetics and biopharmaceutical group with a comprehensive R&D platform, broad product pipeline and established sales network. The collaboration aligns with its two-wheel drive strategy to expand both medical-aesthetic and biopharmaceutical businesses.